235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP

Patient Square Capital LP acquired a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm acquired 235,498 shares of the biopharmaceutical company's stock, valued at approximately $2,049,000. Ocular Therapeutix comprises 0.8% of Patient Square Capital LP's holdings, making the stock its 10th largest position. Patient Square Capital LP owned 0.15% of Ocular Therapeutix as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in OCUL. Atlas Capital Advisors LLC purchased a new stake in Ocular Therapeutix in the second quarter worth $34,000. Amalgamated Bank increased its position in Ocular Therapeutix by 37.9% in the second quarter. Amalgamated Bank now owns 5,384 shares of the biopharmaceutical company's stock worth $37,000 after buying an additional 1,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 1,015 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in Ocular Therapeutix in the third quarter worth $70,000. Finally, Algert Global LLC purchased a new stake in Ocular Therapeutix in the second quarter worth $69,000. 59.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $9.01, for a total transaction of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares of the company's stock, valued at $2,424,221.59. This represents a 1.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Stock Down 0.1 %

Shares of Ocular Therapeutix stock traded down $0.01 during midday trading on Wednesday, hitting $9.48. The company had a trading volume of 828,484 shares, compared to its average volume of 1,818,825. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. The stock has a market capitalization of $1.49 billion, a P/E ratio of -7.19 and a beta of 1.19. The company has a 50 day moving average of $10.02 and a 200 day moving average of $8.33. Ocular Therapeutix, Inc. has a 52-week low of $3.24 and a 52-week high of $11.77.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Robert W. Baird reduced their price target on Ocular Therapeutix from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Thursday, August 8th. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday. Finally, Scotiabank started coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $22.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $16.71.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.